Australia Sues 3M for Over A$2 Billion Over PFAS Firefighting Foam Contamination 
Universal Music Group Rejects Pershing Square Takeover Proposal 
US Quantum Stocks Surge After $2 Billion Government Investment 
SpaceX IPO Could Become Largest in History with $1.8 Trillion Valuation Target 
CTOC Goes Live on Bitget Wallet Trading, Expanding Global Access to AI-Powered Healthcare Data Ecosystem 
MongoDB Q1 FY2027 Earnings Beat Expectations, Raises Full-Year Outlook 
Samsung Union Dispute Escalates Over Semiconductor Bonus Vote 
Salesforce Q1 FY2027 Earnings Beat Expectations Despite Soft Q2 Revenue Outlook 
JPMorgan Sees Biotech Sector at Turning Point, Upgrades Top Pharma Stocks 
Samsung Workers Approve Wage Deal, Avoiding Major Strike and Boosting Chip Supply Confidence 
Blue Origin New Glenn Rocket Explodes During Launch Pad Test, Delaying Space Ambitions 
Synopsys Q2 FY2026 Earnings Beat Driven by AI and Semiconductor Demand 
HP Q2 2026 Earnings Beat Expectations Despite Memory Chip Pressure 
Mega IPOs Like SpaceX and OpenAI Could Reshape S&P 500 and Nasdaq 100 Portfolios in 2026 
Xiaomi Shares Drop After Weak Q1 Earnings Amid Rising Smartphone Costs 
Snowflake Stock Soars 30% After Q1 Earnings Beat and Major AWS AI Partnership 
Meta Subscription Push Could Add Billions in Recurring Revenue, Says Rosenblatt 
Illumina, Inc., a leader in DNA sequencing and array technologies, has launched a pilot proteomics program analyzing 50,000 UK Biobank samples. In collaboration with deCODE Genetics, GSK, Novartis, and others, the initiative utilizes Illumina’s next-gen proteomics assay, Protein Prep™, powered by SOMAmer® technology. This solution promises scalable access to proteomic insights, enabling advancements in drug discovery and disease research.
Proteomics, which examines protein functions and biomarkers, supports breakthroughs in cancer, cardiovascular disease, and other conditions. Illumina’s high-throughput Protein Prep technology enhances protein quantitative trait loci (pQTL) discovery, linking genetic variations to protein expression and disease phenotypes.
UK Biobank will contribute 50,000 samples, including 30,000 funded by Illumina, deCODE Genetics, and Standard BioTools. The samples will be processed using NovaSeq™ X Plus and the DRAGEN Protein Quantification pipeline. Data from these samples will be shared with researchers in 2025. For the remaining 20,000 samples, consortium members will receive exclusive access before release to the broader scientific community.
Illumina aims to deliver rich proteomics data to accelerate medical research. “This project will generate high-quality data, advancing biological insights for researchers and pharma partners,” said Steve Barnard, CTO of Illumina.
UK Biobank Principal Investigator Sir Rory Collins praised the program’s potential to enhance understanding of genetics, environment, and lifestyle in disease development. Standard BioTools CEO Michael Egholm highlighted the transformative potential of combining SOMAmer multiplexing with next-gen sequencing.
The Illumina Protein Prep assay detects 9,000 proteins using 11,000 SOMAmer reagents and supports multiomics studies on NovaSeq platforms. Full launch is expected in early 2025.
This pilot marks a milestone in proteomics, fostering collaboration between researchers and industry leaders to advance global healthcare.
